Advertisement

Topics

I-Mab Biopharma gets rights to myeloma drug for China in up to $120 million deal

06:38 EST 4 Dec 2017 | thePharmaLetter

MorphoSys has entered into an agreement with Shanghai-based I-Mab Biopharma granting the latter an exclusive…

Original Article: I-Mab Biopharma gets rights to myeloma drug for China in up to $120 million deal

NEXT ARTICLE

More From BioPortfolio on "I-Mab Biopharma gets rights to myeloma drug for China in up to $120 million deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...